[1]王 智,解 飞,杨林琪,等.食管癌新辅助治疗的研究[J].医学信息,2022,35(08):56-60.[doi:10.3969/j.issn.1006-1959.2022.08.014]
 WANG Zhi,XIE Fei,YANG Lin-qi,et al.Study on Neoadjuvant Therapy for Esophageal Cancer[J].Medical Information,2022,35(08):56-60.[doi:10.3969/j.issn.1006-1959.2022.08.014]
点击复制

食管癌新辅助治疗的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
56-60
栏目:
综述
出版日期:
2022-04-15

文章信息/Info

Title:
Study on Neoadjuvant Therapy for Esophageal Cancer
文章编号:
1006-1959(2022)08-0056-05
作者:
王 智解 飞杨林琪
(川北医学院临床医学系,四川 南充 637000)
Author(s):
WANG ZhiXIE FeiYANG Lin-qiet al.
(Department of Clinical Medicine,North Sichuan Medical College,Nanchong 637000,Sichuan,China)
关键词:
食管癌新辅助放疗新辅助化疗新辅助放化疗
Keywords:
Esophageal cancerNeadjuvant radiotherapyNeoadjuvant chemotherapyNeoadjuvant chemoradiotherapy
分类号:
R571
DOI:
10.3969/j.issn.1006-1959.2022.08.014
文献标志码:
A
摘要:
食管癌是世界第9大常见恶性肿瘤和第6大癌症相关死亡原因,单纯手术治疗5年生存率不足30%。新辅助治疗是未来局部进展期食管癌治疗的主要研究方向之一。目前大部分研究结果认为新辅助治疗能为食管癌患者带来更好的预后,但各种新辅助治疗方案孰优孰劣,现阶段仍具争议。本文对常见的几种新辅助治疗模式的研究现状作一综述。
Abstract:
Esophageal cancer is the ninth most common malignant tumor and the sixth leading cause of cancer-related death in the world. The 5 - year survival rate of surgical treatment alone is less than 30 %. Neoadjuvant therapy is one of the main research directions in the treatment of locally advanced esophageal cancer in the future. At present, most studies suggest that neoadjuvant therapy can bring better prognosis for patients with esophageal cancer, but the advantages and disadvantages of various neoadjuvant therapy schemes are still controversial. In this paper, the research status of several common new adjuvant therapies is reviewed.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.[3]Watanabe M,Otake R,Kozuki R,et al.Recent progress in multidisciplinary treatment for patients with esophageal cancer[J].Surg Today,2019,50(1):12-20.[4]Arnott SJ,Duncan W,Gignoux M,et al.Preoperative radiotherapy for esophageal carcinoma[J].Cochrane Database Syst Rev,2005(4):CD001799.[5]Chan K,Saluja R,Delos SK,et al.Neoadjuvant treatments for locally advanced,resectable esophageal cancer:A network meta-analysis[J].Int J Cancer,2018,143(2):430-437.[6]Song Y,Tao G,Guo Q,et al.Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adencarcinoma[J].Oncotarget,2016,7(16):21347-21352.[7]Pang Q,Wei X,Zhang W,et al.Annual report of the esophageal cancer radiation group of the Department of Radiotherapy,Tianjin Medical University Cancer Institute & Hospital[J].Ann Transl Med,2020,8(18):1156. [8]Wong C,Law S.Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer[J].J Thorac Dis,2017,9(S8):S773-S780.[9]Ando N,Iizuka T,Ide H,et al.Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study-JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.[10]Ando N,Kato H,Igaki H,et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus JCOG9907[J].Ann Surg Oncol,2012,19(1):68-74.[11]Allum WH,Stenning SP,Bancewicz J,et al.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J].J Clin Oncol,2009,27(30):5062-5067.[12]Ychou M,Boige V,Pignon JP,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase Ⅲ trial[J].J Clin Oncol,2011,29(13):1715-1721.[13]Kelsen DP,Winter KA,Gunderson LL,et al.Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J].J Clin Oncol,2007,25(24):3719-3725.[14]Boonstra JJ,Kok TC,Wijnhoven BP,et al.Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma:long-term results of a randomized controlled trial[J].BMC Cancer,2011(11):181.[15]Chan K,Saluja R,Delos SK,et al.Neoadjuvant treatments for locally advanced,resectable esophageal cancer:A network meta-analysis[J].Int J Cancer,2018,143(2):430-437.[16]陈德河,张邦明.术前新辅助化疗联合手术切除治疗局部晚期食管癌的疗效观察[J].中国肿瘤外科杂志,2018,10(4):245-247.[17]郑晓东,张卫民,侯建彬.新辅助化疗联合微创手术治疗局部进展期食管癌安全性及远期疗效分析[J].中国现代医药杂志,2019,21(7):39-42.[18]何纯,贺云靖,刘铮,等.食管癌根治术联合新辅助化疗治疗食管癌的疗效及对预后的影响[J].癌症进展,2019,17(24):2931-2934.[19]van Hagen P,Hulshof M,van Lanschot J,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.[20]Tepper J,Krasna MJ,Niedzwiecki D,et al.Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.[21]Mariette C,Dahan L,Mornex F,et al.Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer:final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J].J Clin Oncol,2014,32(23):2416-2422.[22]Deng HY,Wang WP,Wang YC,et al.Neoadjuvant chemoradiotherapy or chemotherapy?A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J].Eur J Cardiothorac Surg,2017,51(3):421-431.[23]Yang H,Liu H,Chen Y,et al.Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus(NEOCRTEC5010):A Phase Ⅲ Multicenter,Randomized,Open-Label Clinical Trial[J].J Clin Oncol,2018,36(27):2796-2803.[24]郭旭峰,叶波,杨煜,等.局部进展期食管癌新辅助治疗后微创手术可行性分析的病例对照研究[J].中国胸心血管外科临床杂志,2018,25(3):203-207.[25]Klevebro F,Alexandersson V,Wang N,et al.A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J].Ann Oncol,2016,27(4):660-667.[26]von Dobeln GA,Klevebro F,Jacobsen AB,et al.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction:long-term results of a randomized clinical trial[J].Dis Esophagus,2018,31(13):155.[27]Pasquali S,Yim G,Vohra RS,et al.Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma[J].Ann Surg,2017,265(3):481-491.[28]Jing SW,Qin JJ,Liu Q,et al.Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer:a meta-analysis[J].Future Oncology,2019,15(20):2413-2422.[29]Xin Z,Ren Y,Yong H,et al.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction:A meta-analysis based on clinical trials[J].PLoS One,2018,13(8):e0202185.[30]Pucher PH,Rahman SA,Walker RC,et al.Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus:Inverse propensity score weighted analysis[J].European Journal of Surgical Oncology,2020,46(12):2248-2256.[31]Ruhstaller T,Thuss-Patience P,Hayoz S,et al.Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer:a randomized,open-label,phase Ⅲ trial(SAKK 75/08)[J].Ann Oncol,2018,29(6):1386-1393.[32]Lockhart AC,Reed CE,Decker PA,et al.Phase Ⅱ study of neoadjuvant therapy with docetaxel,cisplatin,panitumumab,and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus(ACOSOG Z4051)[J].Ann Oncol,2014,25(5):1039-1044.[33]Zhang W,Pang Q,Zhang X,et al.Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor[J].Cancer Science,2017,108(4):590-597.[34]Hong MH,Kim HR,Park SY,et al.A phase Ⅱ trail of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)[J].J Clin Oncol,2019,37(15):4027.[35]Kelly RJ,Smith KN,Anagnostou V,et al.Neoadjuvant nivolumab plus concurrent chemoradiation in stage Ⅱ/Ⅲ esophageal/gastroesophageal junction cancer[J].Journal of Clinical Oncology,2019,37(4_suppl):142.[36]Ende T,Clercq N,Henegouwen M,et al.A phase Ⅱ feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma:The PERFECT trial[J].Journal of Clinical Oncology,2019,37(15_suppl):4045.

相似文献/References:

[1]汪 兵,杜 铭.食管癌微创手术与机器人手术的研究[J].医学信息,2018,31(06):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
 WANG Bing,DU Ming.Study on Minimally Invasive Surgery and Robotic Surgery for Esophageal Carcinoma[J].Medical Information,2018,31(08):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
[2]许益芬.三维适型放疗与调强放疗在胸中段食管癌根治性放疗中的 剂量学比较[J].医学信息,2018,31(13):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
 XU Yi-fen.Dosimetric Comparison of Three-dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Radical Radiotherapy of Middle Thoracic Esophageal Carcinoma[J].Medical Information,2018,31(08):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
[3]茹仙古丽·艾尔西丁,木拉提·哈米提,严传波,等.RF和C4.5决策树在食管癌图像分类中的研究[J].医学信息,2018,31(22):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
 Roxangvl·Arxidin,Murat·Hamit,YAN Chuan-bo,et al.Research on RF and C4.5 Decision Tree in Image Classification of Esophageal Cancer[J].Medical Information,2018,31(08):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
[4]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
 WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Medical Information,2018,31(08):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[5]张小艳,赵 红,郑穗生,等.食管癌患者放射性肺损伤预测因素分析及其与 COPD的相关性研究[J].医学信息,2019,32(14):68.[doi:10.3969/j.issn.1006-1959.2019.14.022]
 ZHANG Xiao-yan,ZHAO Hong,ZHENG Sui-sheng,et al.Predictive Factors Analysis of Radiation-Induced Lung Injury in Patients with Esophageal Cancer and Its Correlation with COPD[J].Medical Information,2019,32(08):68.[doi:10.3969/j.issn.1006-1959.2019.14.022]
[6]杨玥欣,汪 志,杨 欣,等.食管癌放疗的剂量学和临床疗效研究[J].医学信息,2020,33(04):72.[doi:10.3969/j.issn.1006-1959.2020.04.022]
 YANG Yue-xin,WANG Zhi,YANG Xin,et al.Dosimetry and Clinical Efficacy of Radiotherapy for Esophageal Cancer[J].Medical Information,2020,33(08):72.[doi:10.3969/j.issn.1006-1959.2020.04.022]
[7]刘安东,刘崇华,王园园.参麦注射液联合放射治疗对中晚期食管癌老年患者的疗效[J].医学信息,2020,33(16):152.[doi:10.3969/j.issn.1006-1959.2020.16.048]
 LIU An-dong,LIU Chong-hua,WANG Yuan-yuan.The Effect of Shenmai Injection Combined with Radiotherapy on Elderly Patients with Advanced Esophageal Cancer[J].Medical Information,2020,33(08):152.[doi:10.3969/j.issn.1006-1959.2020.16.048]
[8]赵素素,谭洁琼,党 娟.食管癌术后恢复期补液量与术后恢复的关系[J].医学信息,2021,34(04):88.[doi:10.3969/j.issn.1006-1959.2021.04.023]
 ZHAO Su-su,TAN Jie-qiong,DANG Juan.The Relationship Between the Amount of Fluid Supplementation in the Recovery Period and Postoperative Recovery of Esophageal Cancer[J].Medical Information,2021,34(08):88.[doi:10.3969/j.issn.1006-1959.2021.04.023]
[9]吴伯勋,刘 浩,刘洪利.香砂六君子汤在微创食管癌切除术后肠功能恢复中的应用效果[J].医学信息,2021,34(06):169.[doi:10.3969/j.issn.1006-1959.2021.06.045]
 WU Bo-xun,LIU Hao,LIU Hong-li.Application Effect of Xiangsha Liujunzi Decoction in Recovery of Bowel Function After Minimally Invasive Esophageal Cancer Resection[J].Medical Information,2021,34(08):169.[doi:10.3969/j.issn.1006-1959.2021.06.045]
[10]王成师,何中祥,蒋书凤,等.同步放化疗在食管癌术后纵隔淋巴结转移患者中的应用[J].医学信息,2021,34(21):156.[doi:10.3969/j.issn.1006-1959.2021.21.044]
 WANG Cheng-shi,HE Zhong-xiang,JIANG Shu-feng,et al.Application of Concurrent Chemoradiotherapy in Patients with Mediastinal Lymph Node Metastasis After Esophagectomy[J].Medical Information,2021,34(08):156.[doi:10.3969/j.issn.1006-1959.2021.21.044]

更新日期/Last Update: 1900-01-01